Dolutegravir (Tivicay) belongs to the class of antiretroviral drugs known as integrase inhibitors. The drug acts against the integrase protein of HIV, blocking their ability to integrate their genetic code into human cells.
Received marketing approval from the US Food and Drug Administration (FDA) in 2013 and Europe in January 2014 for use by adults and adolescents over 12 years of age.
Dolutegravir is formulated as a 50 mg yellow tablet. The dose of dolutegravir is 50 mg (one tablet) once daily or twice daily if taken with efavirenz, nevirapine, tipranavir or HIV known to be resistant to integrase inhibitors. It can be taken with ours without food.
Dolutegravir is also available as part of a fixed dose combination pill called Triumeq. Look Triumeq for more details.
Clinical trials leading to dolutegravir approval show that the three drug regimens containing the drug are highly effective and well tolerated. Several studies have shown that dolutegravir-based treatment is superior to treatment with darunavir / ritonavir or efavirenz in previously untreated people.